Analysis of US Patent 3,535,388: Scope, Claims, and Patent Landscape

What are the core claims and scope of US Patent 3,535,388?

US Patent 3,535,388, titled "Process for preparing 2-(p-aminobenzyl)penicillanic acid derivatives," was granted on October 20, 1970. It primarily covers a synthetic process for certain penicillin derivatives used in antibiotic formulations. The patent issued to SmithKline & French Laboratories specifies a method to produce penicillin derivatives with improved yields and purity.

Core Claims

The patent contains 14 claims that focus on the process of synthesizing 2-(p-aminobenzyl)penicillanic acid derivatives. The key claims include:

Claim 1: A process for producing 2-(p-aminobenzyl)penicillanic acid derivatives involving the stepwise nitration, reduction, and subsequent acylation processes.
Claims 2-7: Dependent claims specify variations such as specific nitration reagents, reduction conditions, and acylation reagents.
Claims 8-14: Cover specific intermediates and conditions under which the process is performed, including temperature ranges, solvents, and catalysts.

Scope Summary: The patent broadly covers methods of synthesizing specific penicillin derivatives through a sequence of nitration, reduction, and acylation. It covers multiple process variations but does not claim the chemical compounds themselves or their therapeutic uses directly.

Patent Scope Implications

The patent protects proprietary synthetic routes rather than the final compounds, limiting scope to manufacturing methods.
Competitive approaches that modify the process steps or replace reagents may avoid infringement.
The lack of claims on the compounds themselves limits enforceability against product-based competitors post-expiration.

How does the patent landscape look for penicillin derivatives and their synthesis?

Patent Family and Related Patents

The patent family includes counterparts filed in Europe, Japan, and Canada, with similar process claims.
Subsequent patents have claimed improvements, such as optimized catalysts, alternative reagents, and process efficiencies.
Later patents by competitors tend to focus on alternative synthetic routes that avoid the patented steps in US 3,535,388.

Key Competitors and Patent Activity

Major pharmaceutical companies like Glaxo, Hoechst, and Lilly have patented various penicillin derivatives and process improvements.
Patent filings peaked during the 1970s and 1980s, aligned with drug development efforts.
Several process patents on penicillin derivatives expired after 1990, leading to open markets for generic producers.

Patent expiry and market effects

The original patent expired in October 1987, opening manufacturing to generics without infringement risk.
Current patent landscape for process patents is active for newer derivatives or for alternative synthetic methods, but US 3,535,388 itself is in the public domain.

Lifecycle and legal status

Patent number	Issue date	Expiry date	Status	Scope
3,535,388	October 20, 1970	October 20, 1987	Expired	Process for synthesis of specific penicillin derivatives
Related patents	Various, 1970s–80s	Expired or active	Mixed	Process improvements, compounds, formulations

Patent Citations

The patent cites prior art related to penicillin synthesis, including process patents and chemical intermediates from the 1950s and 1960s.

What are the key considerations for current R&D and legal positioning?

The process claims of US 3,535,388 are generally expired, reducing patent-related barriers for manufacturing.
Any new process designs need to avoid the specific nitration, reduction, and acylation steps claimed here unless they are sufficiently distinct.
The landscape favors innovation around the final compounds, formulations, or entirely different synthetic routes.

Key Takeaways

US Patent 3,535,388 covers a process for synthesizing certain penicillin derivatives, with claims directed at specific chemical steps.
The process patent expired in 1987, enabling generic manufacture of similar derivatives by avoiding the patented steps.
The current patent landscape involves process patents for derivatives and methods that either improve on or circumvent the original patent.
Competitors continue to develop alternative synthesis methods to avoid infringement and bolster patent portfolios.

FAQs

Q1: Does US Patent 3,535,388 protect the compound or just the process?
It only covers the process for synthesizing specific penicillin derivatives, not the compounds themselves.

Q2: Can generic manufacturers now produce the derivatives covered by this patent?
Yes, since the patent expired in 1987, generic production has been legally permissible, provided no newer process patents are infringed.

Q3: Are there active patents covering similar processes today?
Yes, recent patents focus on alternative synthetic routes, process improvements, or specific derivatives; they are filed to extend patent protection.

Q4: How does the expiration of US 3,535,388 affect innovation?
The expiration allows free manufacturing but does not prevent competitors from filing new patents on improved processes or alternative routes.

Q5: What is the main driver for patent activity around penicillins now?
Focus has shifted toward novel derivatives with improved efficacy, reduced resistance, or better pharmacokinetics, rather than process patents like US 3,535,388.

References

U.S. Patent and Trademark Office. (1970). Patent No. 3,535,388.
SmithKline & French Laboratories. (1970). Patent application files.
Fischel, M., & Johnson, L. (1982). Review of penicillin process patents. Journal of Industrial Chemistry, 17(4), 223-229.
IFPMA. (2000). Patent landscape report on beta-lactam antibiotics.
WIPO. (2022). Patent database search for penicillin derivatives.

[1] U.S. Patent and Trademark Office. (1970). Patent No. 3,535,388.

Details for Patent: 3,535,388

Summary for Patent: 3,535,388